Back to News
Market Impact: 0.32
Tuesday's First Moves: BE Joining SPX, AMGN & NVS Fall, PANW Downgrade
Source: youtube.com
Healthcare & BiotechCompany Fundamentals
Amgen shares sold off after Novartis failed to meet the primary endpoint in a Phase 3 clinical trial. The trial setback triggered volatile trading across healthcare-related stocks, though the article provides no trial data, financial magnitude, or direct explanation of Amgen's exposure.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.45
Ticker Sentiment
AMGN-0.35
NVS-0.80
More News
- Newamsterdam Pharma stock hits 52-week low at 19.57 USD
- Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
- AbbVie's Dividend Survived Humira's Patent Cliff. Will Merck and Amgen's?
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.